We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ion Transport Protein Linked to Brain Cancer Cell Migration and Invasion

By LabMedica International staff writers
Posted on 22 May 2012
By elaborating the molecular interactions of the ion transport protein NKCC1(Na+-K+-Cl-cotransporter 1) cancer researchers have garnered new insights into the forces that drive glioblastoma multiforme cell migration and invasion.

Glioblastoma multiforme (GBM) is an aggressive brain tumor, fatal within one year from diagnosis in most patients despite intensive treatment with surgery, radiation, and chemotherapy. More...
The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment.

NKCC proteins are membrane transport proteins that transport sodium (Na), potassium (K), and chloride (Cl) ions across the cell membrane. They maintain electroneutrality by moving two positively charged solutes (sodium and potassium) alongside two parts of a negatively charged solute (chloride). NKCC1 is known to regulate cell volume and intracellular chloride concentration and to play an important role in brain tumor-cell invasion.

Researchers at Johns Hopkins University (Baltimore, MD, USA) investigated (1) whether the expression of NKCC1 in human tumors correlated with tumor grade; (2) whether NKCC1 affected cell contractility and migration; (3) whether NKCC1 could have an effect on the interaction between the cells and the cells' adhesion substratum; and (4) whether a signaling mechanism involved in the regulation of NKCC1 by promigratory factors existed in GB cells.

Results published in the May 1, 2012, online edition of the journal PLoS Biology revealed that in addition to its conventional function as an ion transporter, NKCC1 also interacted with the cytoskeleton and affected brain tumor-cell migration by acting as an anchor that transduced contractile forces from the plasma membrane to the extracellular matrix en route to cell migration. Regulation of NKCC1 by a family of unconventional enzymes, the WNK kinases, was an important factor that affected the activity of NKCC1 and determined the invasive ability of brain tumor cells. NKCC1 expression correlated with in vivo glioma aggressiveness, and the transporter activity modulated migration speed and invasiveness of cells derived from various human GBs.

“The biggest challenge in brain cancer is the migration of cancer cells. We cannot control it,” said senior author Dr. Alfredo Quinones-Hinojosa, associate professor of neurosurgery and oncology at Johns Hopkins University. “If we could catch these cells before they take off into other parts of the brain, we could make malignant tumors more manageable, and improve life expectancy and quality of life. This discovery gives us hope and brings us closer to a cure.”

Related Links:
Johns Hopkins University




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.